Clinical Trials Browser

Melanoma

NCT04594187 2026-02-17

MelPORT

Phase 2 Recruiting

168 enrolled

Dermatologic

Melanoma

NCT07407166 2026-02-17

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Phase NA Recruiting

40 enrolled

Dermatologic

Melanoma

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Active not recruiting

72 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

NCT06146920 2025-11-18

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Phase NA Active not recruiting

39 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06627595 2024-11-15

APiTOXMM

Recruiting

160 enrolled

Dermatologic

Melanoma, Motor Activity

NCT03370861 2024-09-05

MINING

Terminated

54 enrolled

Dermatologic

Autoimmune Diseases, Carcinoma, Basal Cell, Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell

NCT05478876 2024-08-21

CYCLE

Phase NA Recruiting

9 enrolled

Dermatologic

Melanoma

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase 1 Completed

73 enrolled

Dermatologic

Melanoma

NCT04435964 2023-03-24

G-DEFINER

Completed

247 enrolled

BreastDermatologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Urogenital Neoplasms

NCT01176461 2023-01-18

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Phase 1 Completed

127 enrolled

Dermatologic

Melanoma

NCT00101166 2018-02-28

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Phase 2 Completed

43 enrolled 6 charts

Dermatologic

Melanoma

NCT00610389 2010-05-10

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors

Phase 2 Unknown

27 enrolled

DermatologicGastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma

Clinical Trials

Match Mel

MelPORT

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

APiTOXMM

MINING

CYCLE

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

G-DEFINER

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors